Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial
@article{Prospero2007NeurologicalEO, title={Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial}, author={N. D. Prospero and A. Baker and N. Jeffries and K. Fischbeck}, journal={The Lancet Neurology}, year={2007}, volume={6}, pages={878-886} }
BACKGROUND
Friedreich's ataxia (FA) is a progressive, multisystem, degenerative disorder caused by a reduction in frataxin. Loss of frataxin results in mitochondrial dysfunction and oxidative damage in patients and model systems. Previous studies have indicated that the antioxidant idebenone (5 mg/kg daily) reduces cardiac hypertrophy, but definite improvement in neurological function has not been shown.
METHODS
48 genetically confirmed FA patients, aged 9-17 years, were enrolled in a 6-month… CONTINUE READING
Supplemental Clinical Trials
Interventional Clinical Trial
This study will determine whether a drug called idebenone is safe and effective in reducing
the level of oxidants that are believed to damage the nervous system and hearts in patients… Expand
Conditions | Friedreich Ataxia |
---|---|
Intervention | Drug |
Figures, Tables, and Topics from this paper
252 Citations
Combined Therapy with Idebenone and Deferiprone in Patients with Friedreich’s Ataxia
- Psychology, Medicine
- The Cerebellum
- 2010
- 121
Efficacy and safety of idebenone in the treatment of Friedreich ataxia: a review of early results and future prospects
- Medicine
- 2008
- 1
- Highly Influenced
Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study
- Medicine
- Journal of Neurology
- 2011
- 75
Double-blind, randomized and controlled trial of EPI-743 in Friedreich's ataxia.
- Medicine
- Neurodegenerative disease management
- 2018
- 29
Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA).
- Medicine
- American heart journal
- 2011
- 104
A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia.
- Medicine
- Archives of neurology
- 2010
- 146
- Highly Influenced
- PDF
A0001 in Friedreich ataxia: Biochemical characterization and effects in a clinical trial
- Psychology, Medicine
- Movement disorders : official journal of the Movement Disorder Society
- 2012
- 61
- PDF
References
SHOWING 1-10 OF 25 REFERENCES
Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia.
- Medicine
- Archives of neurology
- 2007
- 75
- PDF
Heart Hypertrophy and Function Are Improved by Idebenone in Friedreich's Ataxia
- Biology, Medicine
- Free radical research
- 2002
- 85
Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia.
- Biology, Medicine
- Human molecular genetics
- 2004
- 119
- PDF
Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders.
- Medicine
- Drugs & aging
- 1994
- 86
A cellular model for Friedreich Ataxia reveals small-molecule glutathione peroxidase mimetics as novel treatment strategy.
- Biology, Medicine
- Human molecular genetics
- 2002
- 93
- PDF